anti-Infliximab ELISA Kit (Remsima®) (ab237659)
Key features and details
- Sensitivity: 30 ng/ml
- Range: 62 ng/ml - 500 ng/ml
- Sample type: Plasma, Serum
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Human
Overview
-
Product name
anti-Infliximab ELISA Kit (Remsima®)
See all Infliximab kits -
Detection method
Colorimetric -
Precision
Intra-assay Sample n Mean SD CV% Overall Inter-assay Sample n Mean SD CV% Overall -
Sample type
Serum, Plasma -
Assay type
Sandwich (quantitative) -
Sensitivity
30 ng/ml -
Range
62 ng/ml - 500 ng/ml -
Recovery
Sample specific recovery Sample type Average % Range Serum 85% - 115% -
Assay duration
Multiple steps standard assay -
Species reactivity
Reacts with: Human -
Product overview
The anti-infliximab ELISA Kit (ab237659) is a highly specific and sensitive kit designed for the in vitro determination of the antibody against Infliximab in biological matrices such as human serum and plasma.
Infliximab (CT-P13) (Remsima®) is a chimeric monoclonal antibody and used to treat auto-immune disorders. Infliximab reduces the amount of active human tumor necrosis factor alpha (hTNFα) in the body by binding to it and preventing it from signaling the receptors for TNFα on the surface of various cell types. Infliximab is used for the treatment of psoriasis, Crohn’s disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis. In controlled trials, clinical response rates of 20-40% have been achieved with above-mentioned regimens in Crohn’s disease and rheumatoid arthritis. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects.
-
Platform
Microplate
Properties
-
Storage instructions
Store at +4°C. Please refer to protocols. -
Components 96 tests Micro ELISA Plate 1 unit Infliximab Standard 1 1 x 1ml Infliximab Standard 2 1 x 1ml Infliximab Standard 3 1 x 1ml Infliximab Standard 4 1 x 1ml Infliximab Standard 5 1 x 1ml Infliximab Standard 6 1 x 1ml Infliximab Standard 7 1 x 1ml Assay Buffer 1 x 50ml Confirmation Reagent 1 x 12ml Peroxidase Conjugate 1 x 12ml TMB substrate 1 x 12ml Stop Solution 1 x 12ml Wash buffer (20X) 1 x 50ml Plate sealers 2 units -
Relevance
Infliximab (Remicade®) is a chimeric monoclonal antibody and used to treat auto- immune disorders. Infliximab reduces the amount of active human tumour necrosis factor alpha (hTNFa) in the body by binding to it and preventing it from signaling the receptors for TNFa on the surface of various cell types. TNFa is one of the key cytokines that triggers and sustains the inflammatory reactions. Infliximab is used for the treatment of psoriasis, Crohn’s disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis. -
Alternative names
- human tumour necrosis factor alpha
- Remicade
Images
-
Typical standard curve.
Typical Standard Curve: This standard curve is for demonstration only. A standard curve must be run with each assay.
